These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9509976)

  • 1. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs.
    Tarella C; Castellino C; Locatelli F; Caracciolo D; Corradini P; Falda M; Novarino A; Tassi V; Pileri A
    Bone Marrow Transplant; 1998 Feb; 21(4):401-7. PubMed ID: 9509976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
    Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
    Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial.
    Bolwell BJ; Pohlman B; Andresen S; Kalaycio M; Goormastic M; Wise K; Wakeling A; Dannley R; Overmoyer B
    Bone Marrow Transplant; 1998 Feb; 21(4):369-73. PubMed ID: 9509971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
    Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
    Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
    Jansen J; Thompson EM; Hanks S; Greenspan AR; Thompson JM; Dugan MJ; Akard LP
    Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
    Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D
    Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
    Andrews RG; Briddell RA; Hill R; Gough M; McNiece IK
    Stem Cells; 1999; 17(4):210-8. PubMed ID: 10437984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children.
    González-Vicent M; Madero L; Sevilla J; Ramirez M; Díaz MA
    Bone Marrow Transplant; 2004 Dec; 34(12):1077-81. PubMed ID: 15516942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
    Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee SL; Finkelstein DM; Spitzer TR
    Bone Marrow Transplant; 1998 May; 21(10):1005-10. PubMed ID: 9632273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.
    Faucher C; le Corroller AG; Blaise D; Novakovitch G; Manonni P; Moatti JP; Maraninchi D
    Bone Marrow Transplant; 1994 Dec; 14(6):895-901. PubMed ID: 7536070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.